B
Bluma G. Brenner
Researcher at Jewish General Hospital
Publications - 143
Citations - 6757
Bluma G. Brenner is an academic researcher from Jewish General Hospital. The author has contributed to research in topics: Resistance mutation & Drug resistance. The author has an hindex of 40, co-authored 140 publications receiving 6411 citations. Previous affiliations of Bluma G. Brenner include McGill University Health Centre & McGill University.
Papers
More filters
Journal ArticleDOI
High Rates of Forward Transmission Events after Acute/Early HIV-1 Infection
Bluma G. Brenner,Michel Roger,Jean-Pierre Routy,Daniela Moisi,Michel Ntemgwa,Claudine Matte,Jean-Guy Baril,Réjean Thomas,Danielle Rouleau,Julie Bruneau,Roger LeBlanc,Mario Legault,Cécile Tremblay,Hugues Charest,Mark A. Wainberg +14 more
TL;DR: Early infection accounts for approximately half of onward transmissions in this urban North American study, suggesting therapy at early stages of disease may prevent onward HIV transmission.
Journal Article
High rates of forward transmission events after acute/early HIV-1 infection. Commentary
Deenan Pillay,Martin Fisher,Bluma G. Brenner,Michel Roger,Jean-Pierre Routy,Daniela Moisi,Michel Ntemgwa,Claudine Matte,Jean-Guy Baril,Réjean Thomas,Danielle Rouleau,Julie Bruneau,Roger LeBlanc,Mario Legault,Cécile Tremblay,Hugues Charest,Mark A. Wainberg +16 more
TL;DR: In this article, a population-based phylogenetic approach was used to characterize human immunodeficiency virus (HIV)-transmission dynamics in Quebec, where early infection accounts for approximately half of onward transmissions in this urban North American study.
Journal ArticleDOI
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
Bluma G. Brenner,Dan Turner,Maureen Oliveira,Daniela Moisi,Mervi Detorio,Mauricio Carobene,Richard Marlink,Jonathan M. Schapiro,Michel Roger,Mark A. Wainberg +9 more
TL;DR: V106M may be a signature mutation in clade C patients treated with EFV and may have the potential to confer high-level multi-NNRTI resistance.
Journal ArticleDOI
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance
TL;DR: Differences in regard to replication capacity or fitness may exist among various HIV subtypes and differences in this regard may potentially become magnified under conditions of drug resistance.
Journal ArticleDOI
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
Bluma G. Brenner,Maureen Oliveira,Florence Doualla-Bell,Daniela Moisi,Michel Ntemgwa,Fernando A Frankel,Max Essex,Mark A. Wainberg +7 more
TL;DR: Tenofovir -based regimens will need to be carefully monitored in subtype C infections for the possible selection of K65R, which conferred similar 6.5–10-fold resistance to ten ofovir and five to 25-fold crossresistance to each of abacavir, lamivudine, and didanosine, while not affecting zidovudine susceptibility.